Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTAFR | P25105 | 18/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bepafant SCHEMBL29658830 | 1.00 | PTAFR (1.00) | PTAFRCYP3A4ALOX15OPRK1PDE4D | |
| Bepafant SCHEMBL29603620 | 1.00 | PTAFR (1.00) | PTAFRCYP3A4ALOX15OPRK1PDE4D | |
| Bepafant SCHEMBL10435458 | 1.00 | PTAFR (1.00) | PTAFRCYP3A4ALOX15OPRK1PDE4D | |
| Bepafant SCHEMBL94512 | 1.00 | PTAFR (1.00) | PTAFRCYP3A4ALOX15OPRK1PDE4D | |
| SCHEMBL24442169 | 0.93 | PTAFR (0.87) | PTAFRCYP3A4ALOX15OPRK1PDE4D | |
| SCHEMBL29603717 | 0.93 | PTAFR (0.87) | PTAFRCYP3A4ALOX15OPRK1PDE4D | |
| SCHEMBL24442268 | 0.92 | PTAFR (0.85) | PTAFRCYP3A4ALOX15OPRK1PDE4D | |
| SCHEMBL24442309 | 0.92 | PTAFR (0.84) | PTAFRCYP3A4ALOX15OPRK1PDE4D | |
| SCHEMBL29602738 | 0.92 | PTAFR (0.84) | PTAFRCYP3A4ALOX15OPRK1PDE4D | |
| SCHEMBL24442260 | 0.91 | PTAFR (0.84) | PTAFRCYP3A4ALOX15OPRK1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5104543-A | PREPARATIVE CHROMATOGRAPHIC METHOD OF SEPARATION FOR PREPARING ENANTIOMERICALLY PURE HETRAZEPINES | BOEHRINGER INGELHEIM GMBH (DE) | 1992-04-14 | — | — | US | claimed |
| EP-0450504-A1 | Preparative chromatographic separation for the production of enantiomerically pure hetrazepines | BOEHRINGER INGELHEIM KG (DE) | 1991-10-09 | — | — | EP | claimed |
| US-20230355638-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | BOEHRINGER INGELHEIM INT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230355638-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | BOEHRINGER INGELHEIM INT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-11766443-B2 | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-26 | — | — | US | disclosed |
| US-11766443-B2 | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-26 | — | — | US | disclosed |
| US-20220160725-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2022-05-26 | — | — | US | disclosed |
| WO-2022101377-A1 | CYCLOPENTATHIOPHENE CARBOXAMIDE DERIVATIVES AS PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-19 | — | — | WO | disclosed |
| US-5104543-A | PREPARATIVE CHROMATOGRAPHIC METHOD OF SEPARATION FOR PREPARING ENANTIOMERICALLY PURE HETRAZEPINES | BOEHRINGER INGELHEIM GMBH (DE) | 1992-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160725-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | PTAFR, PDGFRA, F3 | PTAFR 1/4885CYP3A4 952/4885ALOX15 932/4885 |
| US-11766443-B2 | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists | PTAFR, PDGFRA, F3 | PTAFR 1/4885CYP3A4 952/4885ALOX15 932/4885 |
| US-20230355638-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | PTAFR, PDGFRA, F3 | PTAFR 1/4885CYP3A4 952/4885ALOX15 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.